Analysis of the Incidence and Reasons for Temporary Cancellation of Day Surgery: A Retrospective Study.

Purpose: To investigate the incidence and causes of cancellation of day surgery.

Design: This study was a retrospective, observational study and the clinical data were obtained from electronic medical records.

Methods: Data of day surgery from March 1, 2023 to February 29, 2024 were collected in the major operating room in Xiangya Hospital of Central South University, including patients' general conditions, diagnoses, anesthesia methods, and whether surgery was performed.

Caregivers' experiences of caring for non-COVID-19 patients during the pandemic: A qualitative systematic review.

Objective: To investigate caregivers' experiences of caring for non-coronavirus disease (COVID-19) patients to determine their challenges and needs.

Methods: Five electronic databases (PubMed, Web of Science, Ovid, CINAHL, and ClinicalKey) were searched from January 2020 to June 2022. Two authors independently reviewed all studies for eligibility and extracted information on the study aim, sample characteristics, study design, data collection, analysis methods, and so on.

Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.

Genomic studies have established a set of three core-signaling pathways, receptor tyrosine kinase (RTK), p53 and retinoblastoma (Rb) signaling pathways, contributing glioblastoma (GBM) and revealed that dysregulation of at least two pathways is required for GBM progression. In the present study, we investigate efficacy of combination of palbociclib, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, and erlotinib, epidermal growth factor receptor (EGFR) inhibitor in GBM cell systems with different p53 status. Cell proliferation and colony formation assays showed that the combination treatment synergistically suppressed GBM cell proliferation.

PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.

Breast cancer has been emerging as a most common threat among women, thus many efforts were made to find drugs for fighting breast cancer. So far, PI3K (Phosphatidylinositol-4,5-bisphosphate 3-kinase) inhibitors have been believed to be effective drugs until frequent resistance emerged. Recently, PI3K H1047R mutation has been reported to sensitize breast cancer cells to PI3K inhibition by aspirin.